Research Article

Analysis of the B2M Expression in Colon Adenocarcinoma and Its Correlation with Patient Prognosis

Hailian Lin,1,2,3 Kelang Wang,1,2,3 Kebing Zou,1,2,3 Yuanyuan Wang,1,2,3 Gen xiang Que,1,2,3 Xuefeng Yang,1,2,3 and Mengdan Liao4

1Hunan Provincial Clinical Research Center for Metabolic Associated Fatty Liver Disease, the Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang 421002, Hunan, China
2The Affiliated Nanhua Hospital, Department of Gastroenterology, Hengyang Medical School, University of South China, Hengyang 421002, Hunan, China
3The Affiliated Nanhua Hospital, Department of General Practice, Hengyang Medical School, University of South China, Hengyang 421002, Hunan, China
4The Affiliated Nanhua Hospital, Department of Nephrology, Hengyang Medical School, University of South China, Hengyang 421002, Hunan, China

Correspondence should be addressed to Xuefeng Yang; yxf009988@sina.com and Mengdan Liao; liaomengdan2021@163.com

Received 24 May 2022; Accepted 9 June 2022; Published 9 August 2022

Academic Editor: Weiguo Li

Copyright © 2022 Hailian Lin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Colon adenocarcinoma (COAD) is one of the most common malignant tumors in clinics. It is often found at an advanced stage, with high incidence and poor prognosis, and early diagnosis is difficult and treatment methods are limited. In order to find new methods for diagnosis and treatment of COAD, people pay more and more attention to the discovery and functional research of new oncogenes and tumor suppressor genes of COAD. β2-microglobulin (B2M) plays different physiological and pathological roles in tumor cells and nontumor cells. At present, there is no public report on the expression of B2M in COAD. In this study, the expression of B2M mRNA in COAD tissues was compared with that in normal tissues. The relationship between the expression of B2M mRNA and the stage, histological subtype, lymph node metastasis, TP53 mutation, and survival time of COAD was discussed. It was found that B2M is a potential tumor suppressor gene in COAD. The decreased expression of B2M after mutation can cause immune escape of COAD cells, thus affecting the therapeutic effect and prognosis. This study provides a new idea for the prevention and treatment of COAD.

1. Introduction

Colon adenocarcinoma (COAD) is one of the most common malignant tumors in the clinics. It is often found at an advanced stage, with high incidence and poor prognosis, and early diagnosis is difficult and treatment methods are limited. In order to find new methods for diagnosis and treatment of COAD, people pay more and more attention to the discovery and functional research of new oncogenes and tumor suppressor genes of COAD.

β2-microglobulin (B2M) is a serum protein composed of 119 amino acids with a size of 12 kDa [1]. B2M is expressed in all nucleated cells and is an important subunit of major histocompatibility complex (MHC) class I. It plays different physiological and pathological roles in tumor cells and nontumor cells, especially performing important biological functions in immune monitoring [2]. A large number of studies have found that serum B2M protein is closely related to infection [3, 4], cardiovascular and cerebrovascular diseases [5–7], inflammatory bowel disease [8], kidney injury [9], blood system diseases [10–12], amyloidosis [13, 14], and aging-related diseases [15]. At present, there is no public report on the expression of B2M in COAD. The purpose of this study is to use the TCGA database to analyze the difference of the B2M gene mRNA expression between colon cancer tissues and normal colon tissues and its correlation
with the survival prognosis of patients, so as to provide new diagnostic markers and therapeutic targets for colon adenocarcinoma.

2. Methods

2.1. Experimental Methods. The experimental methods are as follows:

(1) TCGA database was used to analyze the expression of B2M mRNA in pan-cancer tissues and corresponding normal tissues. UALCAN (https://ualcan.path.uab.edu/index.html) is an effective online cancer data analysis and mining website based on relevant cancer data in TCGA database. We accessed the TCGA database through the UALCAN website [16] to analyze the expression of B2M mRNA in pan-cancer tissues and corresponding normal tissues.

(2) TCGA database was used to analyze the difference of the B2M mRNA expression between colon adenocarcinoma tissues and normal colon tissues. We accessed the TCGA database through the UALCAN website [16], from which we downloaded 286 colon cancer tissue samples and 41 paracancer normal tissue samples to analyze the difference of the B2M mRNA expression between colon cancer tissues and adjacent normal tissues.

(3) TCGA database was used to analyze the difference of methylation level of a B2M gene promoter between colon adenocarcinoma tissues and normal colon tissues. We accessed the TCGA database through the UALCAN website [16] to analyze the difference of methylation level of the B2M gene promoter between colon cancer tissues and adjacent normal tissues.

(4) TCGA database was used to analyze the relationship between B2M mRNA expression and colon cancer stage. According to the latest TNM staging of malignant tumor, colon cancer can be divided into four stages according to the severity: Stage 1: The primary tumor is only confined to the mucosa or submucosa, and there is no tumor lymph gland metastasis or distant metastasis. Stage 2: The primary tumor invaded the muscular layer of intestinal wall, but there is no tumor lymph gland metastasis or distant metastasis. Stage 3: No matter the depth of primary tumor invasion, regional lymph node metastasis has occurred, but there is no distant metastasis. Stage 4: The tumor had distant metastasis, such as liver, lung, bone, and brain metastasis, peritoneal implantation metastasis, and distant lymph node metastasis(such as supraclavicular lymph node metastasis) [17]. We accessed the TCGA database through the UALCAN website [16] to analyze the relationship between the expression of B2M mRNA and the stage of colon cancer.

(5) TCGA database was used to analyze the relationship between B2M mRNA expression and histological subtypes of colon cancer. The histological types of colon cancer can be divided into the following types: (1) Nonspecific adenocarcinoma. (2) Special types of adenocarcinoma, including mucinous adenocarcinoma, medullary carcinoma, serrated adenocarcinoma, signet-ring cell adenocarcinoma, cribriform acinar adenocarcinoma, and micropapillary adenocarcinoma. (3) Squamous cell carcinoma. (4) Adenosquamous carcinoma. (5) Spindle cell carcinoma/sarcomatoid carcinoma. (6) Undifferentiated carcinoma. (7) Other special types of colon cancer. (8) Type undetermined colon cancer [18]. We accessed the TCGA database through UALCAN website [16] and mainly analyzed the differences of the B2M mRNA expression between adenocarcinoma and mucinous adenocarcinoma.

(6) TCGA database was used to analyze the relationship between the B2M mRNA expression and lymph node metastasis. The status of lymph node metastasis was divided into four grades: N0: no regional lymph node metastasis; N1:1~3 axillary lymph nodes metastasis; N2:4~9 axillary lymph nodes metastasis; N3:more than 10 axillary lymph nodes metastasis. We accessed the TCGA database through the UALCAN website [16] to analyze the relationship between the B2M mRNA expression and lymph node metastasis.

(7) TCGA database was used to analyze the relationship between the B2M mRNA expression and TP53 mutation status. We accessed the TCGA database through the UALCAN website [16] to analyze the relationship between the B2M mRNA expression and TP53 mutation status.

(8) TCGA database was used to analyze the relationship between the B2M mRNA expression and gender, age, weight, and race of patients with colon adenocarcinoma. We accessed the TCGA database through the UALCAN website [16] to analyze the relationship between the B2M mRNA expression and gender, age, weight, and race of patients with colon adenocarcinoma.

(9) TCGA database was used to analyze the relationship between the expression level of B2M mRNA in colon adenocarcinoma tissues and the survival time of patients.

(10) TCGA database was used to analyze the genes related to the B2M gene expression in patients with colon adenocarcinoma.

We accessed the TCGA database through the UALCAN website [16] to analyze the genes related
to the B2M gene expression in colon adenocarcinoma patients.

2.2. Statistical Analysis. Wilcoxon assay was used to analyze the expression levels of B2M mRNA in colon cancer tissues and normal colon tissues. Kaplan–Meier analysis was used to compare the survival time of the B2M mRNA high expression group and low expression group. Log-ranch test was used to calculate the p value, \( P < 0.05 \) indicates statistical significance. All statistical analyses were performed using R (version x64 3.5.1).

3. Results

3.1. Clinical Characteristics of 286 Patients with Colon Cancer in the TCGA Database. We downloaded the clinical data of 286 patients with colon cancer from TCGA database, including patients’ gender, age, weight, race, clinical stage, and histological subtype. After excluding the samples with incomplete clinical data, in the categories of gender, age, weight, clinical stage, and histological subtype, only 283, 283, 210, 274, and 280 samples were left to participate in the statistics; the clinical characteristics are shown in Table 1.

3.2. The Expression of B2M mRNA in Pan-Cancer Tissues and Corresponding Normal Tissues. The expression of B2M mRNA in pan-cancer tissues and corresponding normal tissues is shown in Figure 1. It can be seen that the expression of B2M mRNA is increased in most tumors, such as BRCA \( (p = 1.604910E-03) \), CHOL \( (p = 7.43370000000354E-07) \), ESCA \( (p = 1.635010000000066E-05) \), GBM \( (p = 1.62447832963153E-12) \), HNSC \( (p = 1.62458935193399E-12) \), KICH \( (p = 3.8730999627661E-08) \), KIRC \( (p < 1E-12) \), KIRP \( (p = 1.5612000003848E-07) \), PCPG \( (p < 1E-12) \), THCA \( (p = 3.298440E-03) \). In a few tumors, the expression of B2M mRNA was decreased, such as COAD \( (p < 1E-12) \), LUAD \( (p = 1.62436730732907E-12) \), LUSC \( (p = 1.62458935193399E-12) \), PRAD \( (p = 1.757730E-02) \), and READ \( (p = 1.8222999978745E-08) \). There was no statistically significant difference in the expression of other tumors in Figure 1.

3.3. The Expression of B2M mRNA in Colon Adenocarcinoma Tissues Was Significantly Lower Than That in Normal Colon Tissues. We downloaded 41 samples of normal tissues adjacent to cancer and 286 samples of colon cancer from the TCGA database. It can be seen that the expression of B2M mRNA in colon adenocarcinoma tissues was significantly lower than that in adjacent normal tissues \( (p < 1E-12) \) (Figure 2).

3.4. The Methylation Level of a B2M Gene Promoter in Colon Adenocarcinoma Tissues Was Lower Than That in Normal Colon Tissues. The results of TCGA database analysis showed that the methylation level of B2M gene promoter in colon cancer tissues was lower than that in normal colon tissues, and the difference was statistically significant \( (p = 1.959910E-03) \) (Figure 3). \( \beta \) values indicate DNA methylation levels from 0 (unmethylated) to 1 (fully methylated). Different \( \beta \) value represents hypermethylation \( (\beta \text{ values: 0.7–0.5}) \) or hypomethylation \( (\beta \text{ values: 0.3–0.25}) \).

3.5. The Expression Level of B2M mRNA Was Correlated with the Stage of Colon Adenocarcinoma. The results of TCGA database analysis showed that the expression level of B2M mRNA was correlated with the stage of colon cancer. The difference of B2M mRNA expression between stage I and stage IV, and between stage II and stage IV was statistically significant. The higher the stage of colon cancer, the lower the expression of B2M mRNA \( (\text{normal-vs-stage1: } p = 2.42909999892404E-08; \text{normal-vs-stage2: } p = 2.26879626197274E-11; \text{normal-vs-stage3: } p = 3.4688961200247E-10; \text{normal-vs-stage4: } p = 8.27404811332144E-12; \text{stage1-vs-stage4: } p = 1.609760E-02; \text{stage2-vs-stage4: } p = 3.202300E-03) \) (Figure 4).

3.6. The Expression of B2M mRNA Was Correlated with Histological Subtypes of Colon Adenocarcinoma. The results of TCGA database analysis showed that the expression level of B2M mRNA was correlated with the histological subtypes of colon cancer, and the expression level of B2M mRNA in adenocarcinoma was lower than that in mucinous adenocarcinoma, and the difference was statistically significant \( (\text{normal-vs-adenocarcinoma: } p = 1.34860012046545E-10; \text{normal-vs-mucinous-adenocarcinoma: } p = 2.019200E-04; \text{adenocarcinoma-vs-mucinous-adenocarcinoma: } p = 3.139800E-02) \) (Figure 5).

3.7. The Expression of B2M mRNA Was Not Correlated with Lymph Node Metastasis. TCGA database analysis showed that B2M mRNA expression was not associated with lymph node metastasis \( (\text{normal-vs-N0: } p = 1.79600000513749E-09; \text{normal-vs-N1: } p = 2.0810997368356E-10; \text{normal-vs-N2: } p = 1.10179976253733E-10) \) (Figure 6).

3.8. B2M mRNA Expression Was Correlated with the TP53 Mutation Status. The results of TCGA database analysis showed that the expression level of B2M mRNA in colon adenocarcinoma tissues was correlated with the TP53 mutation status, and the expression level of B2M mRNA in TP53 mutated colon cancer tissues was lower than that in nonmutated colon adenocarcinoma tissues \( (\text{normal-vs-tp53-mutant: } p = 5.69789779021147E-11; \text{normal-vs-tp53-nonmutant: } p = 6.83500001041892E-09; \text{tp53-mutant-vs-tp53-nonmutant: } p = 8.608400E-04) \) (Figure 7).

3.9. The Expression Level of B2M mRNA Was Not Related to Gender, Age, and Weight of Patients with Colon Adenocarcinoma but Was Related to Race. The results of TCGA database analysis showed that the expression level of B2M mRNA in colon cancer tissues was not related to gender.
Table 1: The clinical characteristics of the COAD patients in the TCGA.

| Clinical features          | Classification                              | Percentage (%) |
|----------------------------|---------------------------------------------|----------------|
| Gender, n (%)              | Male                                        | 156 (55.1%)    |
|                            | Female                                      | 127 (44.9%)    |
| Age, n (%)                 | 21–60                                       | 102 (36.0%)    |
|                            | 61–100                                      | 181 (64.0%)    |
| Weight, n (%)              | Normal weight (BMI: 18.5–25)                | 70 (33.3%)     |
|                            | Extreme weight (BMI: 25–30)                 | 74 (35.2%)     |
|                            | Obese (BMI: 30–40)                          | 56 (26.7%)     |
|                            | Extreme Obese (BMI > 40)                    | 10 (4.8%)      |
| Clinical stage, n (%)      | Stage I                                     | 45 (16.4%)     |
|                            | Stage II                                    | 110 (40.2%)    |
|                            | Stage III                                   | 80 (29.2%)     |
|                            | Stage IV                                    | 39 (14.2%)     |
| Histological subtypes, n (%)| Adenocarcinoma                              | 243 (86.8%)    |
|                            | Mucinous adenocarcinoma                     | 37 (13.2%)     |

Figure 1: Expression of the B2M gene in the tumor tissues of the TCGA database.

(normal-vs-male: $p = 2.39808173319034E - 14$; normal-vs-female: $p = 1.8882243179478E - 12$) (figure 8), age (normal-vs-age (21–40yrs): $p = 6.42129999999241E - 05$; normal-vs-age (41–60yrs): $p = 4.14730028097665E - 10$; normal-vs-age (61–80yrs): $p = 1.69331215715829E - 12$; normal-vs-age (81–100yrs): $p = 4.07770000000474E - 05$) (figure 9), and weight (normal-vs-normal weight: $p = 1.24109611476797E - 11$; normal-vs-extreme weight: $p = 8.13670020249901E - 10$; normal-vs-obese: $p = 2.1691999740384E - 08$; normal-vs-extreme obese: $p = 5.7569999999513E - 05$) (Figure 10), but was related to race, and the expression level of B2M mRNA in colorectal cancer
Figure 2: Expression of B2M in COAD based on sample types.

Figure 3: Promoter methylation level of B2M in COAD.

Figure 4: Expression of B2M in COAD based on individual cancer stages.
Expression of B2M in COAD based on histological subtypes

TCGA samples

Figure 5: Expression of B2M in COAD based on histological subtypes.

Expression of B2M in COAD based on nodal metastasis status

TCGA samples

Figure 6: Expression of B2M in COAD based on nodal metastasis status.

Expression of B2M in COAD based on TP53 mutation status

TCGA samples

Figure 7: Expression of B2M in COAD based on TP53 mutation status.
tissues of African Americans was lower than that of Caucasians and Asians (normal-vs-Caucasian: $p = 1.7468 \times 10^{-12}$; normal-vs-African–American: $p = 1.2874 \times 10^{-11}$; normal-vs-Asian: $p = 5.4210 \times 10^{-03}$; Caucasian-vs-African–American: $p = 1.9562 \times 10^{-02}$; African–American-vs-Asian: $p = 2.2698 \times 10^{-02}$) (Figure 11).

3.10. The Expression of B2M mRNA Was Not Associated with the Survival of Patients with Colon Adenocarcinoma. Analysis of TCGA database showed that the expression of B2M mRNA was not associated with the survival of patients with colon cancer ($p = 0.75$) (Figure 12).

3.11. Genes Related to the B2M Gene Expression in Patients with Colon Adenocarcinoma. Using TCGA database, we analyzed the top 25 genes positively correlated (Figure 13) and negatively correlated with B2M gene expression in colon adenocarcinoma patients (Figure 14).

4. Discussion

The results of TCGA database analysis showed that the expression of B2M was increased in most tumors and decreased in a few tumors (Figure 1). Josson et al. reported that overexpression of B2M promotes the growth and progression of renal cell carcinoma, lung cancer, prostate cancer, and breast cancer [19]. Some researchers compared the preoperative serum B2M concentration of 40 patients with renal cell carcinoma and 23 normal controls and found that the preoperative serum B2M level increased in 70% of renal cell carcinoma patients [20]. Since then, researchers have demonstrated that B2M can promote the growth of human renal cell carcinoma [21] by activating the protein kinase A,
cyclic adenosine monophosphate response element binding protein, and vascular endothelial growth factor axis. At the same time, a large number of studies have found that serum B2M levels in lung cancer [22, 23], prostate cancer [24–27], breast cancer [28, 29], and hematological malignancies have also increased [30–32]. We downloaded 41 samples of normal tissue adjacent to cancer and 286 samples of colon cancer from TCGA database. The results showed that the expression of B2M gene in colon cancer tissues was significantly lower than that in adjacent normal tissues.

DNA methylation status of the CpG island is often related to the transcriptional silence of related genes [33, 34]. Some researchers believe that DNA methylation plays a role in regulating HLA class I antigen presentation [35]. At present, there are only a few studies on the methylation status of tumor B2M gene. Gyorffy et al. found that epigenetic hypermethylation can cause loss or downregulation of HLAs and B2M expression in breast cancer [36]. At the same time, some researchers believe that hypermethylation of the B2M gene promoter may affect the antigen presentation of HLA class I molecules, which may lead to immune escape and immunotherapy resistance of colorectal cancer [37]. In addition, Cornelia et al. found that elimination of DNA methylation by DNMT inhibitors upregulated the

---

**Figure 10:** Expression of B2M in COAD based on patient’s weight.

**Figure 11:** Expression of B2M in COAD based on patient’s race.
Effect of B2M expression level on COAD patient survival

![Graph showing the effect of B2M expression level on COAD patient survival. The graph displays survival probability against time in days for high expression (red line, n = 71) and low/medium-expression (blue line, n = 208) with p = 0.75.]

**Figure 12:** Effect of B2M expression level on COAD patient survival.

Expression pattern of input genes in Colon adenocarcinoma (COAD)

![Heatmap showing the expression pattern of input genes in normal and tumor samples. The genes with positive correlation with B2M are highlighted.]

**Figure 13:** Genes positively correlated with B2M in COAD.
expression of B2M at RNA and protein levels [38] in colon adenocarcinoma. However, the analysis of TCGA database showed that the methylation level of B2M gene promoter in colon adenocarcinoma tissues was lower than that in adjacent normal tissues. At the same time, the methylation of B2M gene promoter was at a very low level in both adjacent normal tissues and colon cancer tissues. This suggests that the low expression of B2M in colon cancer tissues may not be caused by methylation of the B2M gene promoter, but by B2M gene mutation [39, 40].

B2M is an important subunit of MHC class I molecules, which plays an antitumor role by promoting MHC class I molecules-mediated tumor antigen presentation and T cell recognition [2]. Therefore, we believe that B2M gene is a tumor suppressor gene in colon cancer, and its low expression in colon cancer tissue can promote the occurrence and development of colon cancer. We then analyzed the expression of B2M in different stages of colon cancer by TCGA database. The results showed that the expression level of B2M mRNA decreased with the progression of colon cancer stage, and the expression levels of B2M mRNA were different between stages I and IV, II and IV. In addition, we can also see that the expression level of B2M mRNA is different between colon adenocarcinoma and mucinous adenocarcinoma. The expression of B2M mRNA in colonic mucinous adenocarcinoma was higher than that in colonic adenocarcinoma.

TP53 is a common tumor suppressor gene, which plays a role in a variety of tumors. Mutations of TP53 are the most common in human tumors and are often associated with poor prognosis [41]. The missense mutation of TP53 is very common in human cancers, which can lead to the inactivation of the tumor suppressive effect of mutant p53 protein, which is conducive to the proliferation and survival of cancer cells, thus promoting tumor invasion, migration and chemotherapy resistance [42, 43]. The frequency of TP53 mutation in colorectal cancer ranged from 40% to 50% [44]. Through TCGA database analysis, we found that the expression level of B2M in colon cancer tissues with TP53 mutation was lower than that without mutation. It is suggested that the low expression of B2M in colon cancer is related to TP53 gene mutation. The expression level of B2M in colon cancer tissues with TP53 mutation is lower, and the tumor is easier to metastasize and more aggressive.

In addition, we also found that the expression level of B2M gene had racial difference, but it was not related to gender, age and weight of patients with colon cancer. The effect of B2M expression level on the prognosis of cancer patients is different. The high expression of B2M gene had racial difference, but it was not related to gender, age and weight of patients with colon cancer.

The effect of B2M expression level on the prognosis of cancer patients is different. The high expression of B2M gene is associated with poor prognosis in most cancer patients. It has been reported that elevated B2M can worsen the prognosis of patients with renal cell carcinoma [45], prostate cancer, breast cancer [29], hematological malignancy [30, 31, 46–48] and glioma [49]. At the same time, Kloor
et al. thought that the B2M mutation was associated with reduced metastasis and recurrence of colon cancer [40, 50, 51]. However, Shrout and Bianchini et al. found that the low expression of B2M was associated with lymph node metastasis and poor prognosis in patients with colorectal cancer [52, 53]. However, we found that the expression level of B2M was not related to the status of lymph node metastasis in patients with colon cancer through TCGA database analysis, which was inconsistent with the results reported in the literature. This may be because the TCGA database analyses tumor metastasis in axillary lymph nodes, while regional lymph node metastasis is the most common in colon cancer. At the same time, different researchers have drawn different conclusions on the impact of B2M expression level on lymph node metastasis and prognosis of colon cancer, so it is necessary to strengthen further research in this area.

To sum up, B2M may be a potential tumor suppressor gene in colon cancer. The decreased expression of B2M after mutation can cause immune escape of colon cancer cells, thus affecting the therapeutic effect and prognosis. However, there are still some contradictions about the role of B2M in colon cancer. Therefore, more research is needed to continue to explore the role of B2M in colon adenocarcinoma.

Data Availability
The data used and/or analyzed during the current study are available from the corresponding author upon request.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Authors’ Contributions
Hailian Lin and Kelang Wang contributed equally to this work.

Acknowledgments
This research was partially supported by the Special Funding for the Construction of Innovative Provinces in Hunan (2021SK4031), the Scientific Research Project of Hunan Provincial Health and Family Planning Commission (A2017015), the Natural Science Foundation of Hunan Province, China (2016JJ5010), and the National Natural Science Foundation of China (81373465).

References
[1] H. L. Ploegh, H. T. Orr, and J. L. Strominger, “Major histocompatibility antigens: the human (HLA-A, -B, -C) and murine(H-2K, H-2D)class I molecules,” Cell, vol. 24, no. 2, pp. 287–299, 1981.
[2] H. Wang, B. Liu, and J. Wei, “Beta2-microglobulin(B2M) in cancer immunotherapies: biological function, resistance and remedy,” Cancer Letters, vol. 517, pp. 96–104, 2021.
[3] S. J. Chiou, H. J. Ko, C. C. Hwang, and Y. R. Hong, “The double-edged sword of beta2-microglobulin in antibacterial properties and amyloid fibril-mediated cytotoxicity,” International Journal of Molecular Sciences, vol. 22, no. 12, p. 6330, 2021.
[4] A. Holch, R. Bauer, L. R. Olari et al., “Respiratory β2-microglobulin exerts pH dependent antimicrobial activity,” Virulence, vol. 11, no. 1, pp. 1402–1414, 2020.
[5] S. Liabeuf, A. Lenglet, L. Desjardins et al., “Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients,” Kidney International, vol. 82, no. 12, pp. 1297–1303, 2012.
[6] P. M. Rist, M. C. Jiménez, and K. M. Ruxrode, “Prospective association between β2-microglobulin levels and ischemic stroke risk among women,” Neurology, vol. 88, no. 23, pp. 2176–2182, 2017.
[7] A. M. Wilson, E. Kimura, R. K. Harada et al., “Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies,” Circulation, vol. 116, no. 12, pp. 1396–1403, 2000.
[8] M. Zissis, A. Afroudakis, G. Galanopoulos et al., “B2 microglobulin: is it a reliable marker of activity in inflammatory bowel disease?” American Journal of Gastroenterology, vol. 96, no. 7, pp. 2177–2183, 2001.
[9] K. T. Barton, A. Kakajiwala, D. J. Dietzen, C. W. Goss, H. Gu, and V. R. Dharnidharka, “Using the newer kidney disease: improving global outcomes criteria, beta-2-microglobulin levels associate with severity of acute kidney injury,” Clinical Kidney Journal, vol. 11, no. 6, pp. 797–802, 2018.
[10] J. Rodriguez, J. Cortes, M. Talpaz et al., “Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia,” Clinical Cancer Research, vol. 6, no. 1, pp. 147–152, 2000 Jan.
[11] S. Gatto, G. Ball, F. Onida, H. M. Kantarjian, E. H. Estey, and M. Beran, “Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS),” Blood, vol. 102, no. 5, pp. 1622–1625, 2003.
[12] L. Melillo, N. Cascavilla, G. Lombardi, M. Carotenuto, and P. Musto, “Prognostic relevance of serum beta 2-microglobulin in acute myeloid leukemia,” Leukemia, vol. 6, no. 10, pp. 1076–1078, 1992.
[13] I. Portales-Castillo, J. Yee, H. Tanaka, and A. Z. Frenves, “Beta-2 microglobulin amyloidosis: past, present, and future,” Kidney, vol. 360, no. 12, pp. 1447–1455, 2020.
[14] A. D. Morris, R. N. Smith, and J. R. Stone, “The pathology and changing epidemiology of dialysis-related cardiac beta-2 microglobulin amyloidosis,” Cardiovascular Pathology, vol. 42, pp. 30–35, 2019.
[15] L. K. Smith, Y. He, J. S. Park et al., “β2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis,” Nature Medicine, vol. 21, no. 8, pp. 932–937, 2015.
[16] D. S. Chandrashekar, S. K. Karthikeyan, P. K. Korla et al., “UALCAN: an update to the integrated cancer data analysis platform,” Neoplasia, vol. 25, pp. 18–27, 2022.
[17] P. Wang and L. Han, TNM Staging of Malignant Tumors, Tianjin Science and technology Translation and Publishing Company, Tianjin, China, 8th edition, 2019.
Evidence-Based Complementary and Alternative Medicine

[18] “Guidelines for the diagnosis and treatment of colorectal cancer in China (2020 edition),” *Chinese Journal of Surgery*, vol. 58, no. 8, pp. 561–585, 2020.

[19] S. Josson, T. Nomura, J. T. Lin et al., “β2-Microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells,” *Cancer Research*, vol. 71, no. 7, pp. 2600–2610, 2011.

[20] C. Selli, F. Cozzolino, M. Carini, R. Lenzi, and D. Vercelli, “Serum beta 2 microglobulin levels in patients with renal cell carcinoma,” *Urological Research*, vol. 12, no. 5, pp. 261–263, 1984.

[21] T. Nomura, W. C. Huang, H. E. Zhai et al., “β2-Microglobulin promotes the growth of human renal cell carcinoma through the activation of the protein kinase A, cyclic AMP–responsive element-binding protein, and vascular endothelial growth factor Axis,” *Clinical Cancer Research*, vol. 12, no. 24, pp. 7294–7305, 2006.

[22] J. Shuster, P. Gold, and M. D. Poulik, “β2-Microglobulin levels in cancerous and other disease states,” *Clinica Chimica Acta*, vol. 67, no. 3, pp. 307–313, 1976.

[23] R. Amand, M. D. Mathur, and N. R. Acharya, “Serum beta-2 microglobulin levels in bronchogenic carcinoma,” *Indian Journal of Thoracic and Cardiovascular Surgery*, vol. 9, no. 2, pp. 96–99, 1993.

[24] Y. X. Zhang, L. Wang, P. Y. Ji, G. G. Zhao, G. P. Zhong, and Z. P. Wang, “Correlation of serum beta-2 microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer,” *Archives of Medical Research*, vol. 44, no. 4, pp. 259–265, 2013.

[25] W. C. Huang, D. Wu, Z. Xie et al., “β2-Microglobulin is a signaling and growth-promoting factor for human prostate cancer bone metastasis,” *Cancer Research*, vol. 66, no. 18, pp. 9108–9116, 2006.

[26] M. Abdul and N. Hoosein, “Changes in beta-2 microglobulin expression in prostate cancer,” *Urologic Oncology: Seminars and Original Investigations*, vol. 5, no. 4, pp. 168–172, 2000.

[27] M. Gross, I. Top, I. Laux et al., “β-2-Microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer,” *Clinical Cancer Research*, vol. 13, no. 7, pp. 1979–1986, 2007.

[28] K. Li, H. Du, X. Lian et al., “Characterization of β-2-microglobulin expression in different types of breast cancer,” *BMC Cancer*, vol. 14, no. 1, p. 750, 2014.

[29] T. Klein, I. Levin, A. Niska et al., “Correlation between tumour and serum beta 2m expression in patients with breast cancer,” *European Journal of Immunogenetics*, vol. 23, no. 6, pp. 417–423, 1996.

[30] J. Yang, J. Qian, M. Wezeman et al., “Targeting β2-microglobulin for induction of tumor apoptosis in human hematological malignancies,” *Cancer Cell*, vol. 10, no. 4, pp. 295–307, 2006.

[31] D. Rossi, M. Fangazio, L. De Paoli et al., “Beta2microglobulin is an independent predictor of progression in asymptomatic multiple myeloma,” *Cancer*, vol. 116, no. 9, pp. 2188–2200, 2010.

[32] C. Yoo, D. H. Yoon, S. Kim et al., “Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma,” *Hematological Oncology*, vol. 34, no. 1, pp. 22–27, 2015.

[33] P. A. Jones, “Epigenetics in carcinogenesis and cancer prevention,” *Annals of the New York Academy of Sciences*, vol. 983, no. 1, pp. 213–219, 2003.

[34] A. P. Feinberg, “Cancer epigenetics takes center stage,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 98, no. 2, pp. 392–394, 2001.

[35] P. J. Van den Elsen, T. M. Holing, H. F. Kuipers, and N. van der Stoep, “Transcriptional regulation of antigen presentation,” *Current Opinion in Immunology*, vol. 16, no. 1, pp. 67–75, 2004.

[36] B. Gyorffy, A. Nagy, L. Pongor et al., “Effect of DNA hypermethylation on immune escape through down-regulation of antigen presentation genes in breast cancer,” *Journal of Clinical Oncology*, vol. 34, Article ID 11547, 2016.

[37] Z. Snahnicanova, I. Kasubova, M. Kalman et al., “Genetic and epigenetic analysis of the beta-2-microglobulin gene in microsatellite instable colorectal cancer,” *Clinical and Experimental Medicine*, vol. 20, no. 1, pp. 87–95, 2020.

[38] S. Cornelia, K. B. Chiappinelli, A. A. Guzzetta et al., “Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells,” *PLoS One*, vol. 12, no. 6, Article ID e0179501, 2017.

[39] D. C. Bicknell, L. Kaklamakis, R. Hampson, W. F. Bodmer, and P. Karran, “Selection for beta-2-Microglobulin mutation in mismatch repair-defective colorectal carcinomas,” *Current Biology*, vol. 6, no. 12, pp. 1695–1697, 1996.

[40] M. Kloor, S. Michel, B. Buckowetz et al., “Beta2-microglobulin mutations in microsatellite unstable colorectal tumors,” *International Journal of Cancer*, vol. 121, no. 2, pp. 454–458, 2007.

[41] C. Kandoth, M. D. McLellan, F. Vandin et al., “Mutational landscape and significance across 12 major cancer types,” *Nature*, vol. 502, no. 7471, pp. 333–339, 2013.

[42] D. Walerych, M. Napoli, L. Collavini, and G. Del Sal, “The rebel angel:mutant p53 as the driving oncogene in breast cancer,” *Carcinogenesis*, vol. 33, no. 11, pp. 2007–2017, 2012.

[43] D. Walerych, K. Lisek, and G. Del Sal, “Mutantp53: one, one and one hundred thousand,” *Frontiers in Oncology*, vol. 5, p. 289, 2015.

[44] B. Iacobetta, “TP53 mutation in colorectal cancer,” *Human Mutation*, vol. 21, no. 3, pp. 271–276, 2003.

[45] T. Rasmusson, K. Grankvist, and B. Ljungberg, “Serum beta-2-microglobulin and prognosis of patients with renal cell carcinoma,” *Acta Oncologica*, vol. 35, no. 4, pp. 479–482, 1996.

[46] T. Nomura, W. C. Huang, H. E. Zhai, S. Josson, H. Mimata, and L. W. Chung, “β2-Microglobulin-mediated signaling as a target for cancer therapy,” *Anti-Cancer Agents in Medicinal Chemistry*, vol. 14, no. 3, pp. 343–352, 2014.

[47] A. M. Tsimberidou, H. M. Kantarjian, S. Wen et al., “The prognostic significance of serum β2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1, 180 patients,” *Clinical Cancer Research*, vol. 14, no. 3, pp. 721–730, 2008.

[48] Y. Nakajima, N. Tomita, R. Watanabe et al., “Serum beta-2 microglobulin level as a useful prognostic marker of Hodgkin lymphoma,” *Blood*, vol. 122, no. 21, p. 4239, 2013.

[49] H. Zhang, B. Cui, Y. Zhou et al., “B2M overexpression correlates with malignancy and immune signatures in human gliomas,” *Scientific Reports*, vol. 11, no. 1, p. 5045, 2021.
[50] A. Tikidzhieva, A. Benner, S. Michel et al., “Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial,” British Journal of Cancer, vol. 106, no. 6, pp. 1239–1245, 2012.
[51] V. H. Koelzer, K. Baker, D. Kassahn, D. Baumhoer, and I. Zlobec, “Prognostic impact of beta-2-microglobulin expression in colorectal cancers stratified by mismatch repair status,” Journal of Clinical Pathology, vol. 65, no. 11, pp. 996–1002, 2012.
[52] M. Bianchini, E. Levy, C. Zucchini et al., “Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa,” International Journal of Oncology, vol. 29, no. 1, pp. 83–94, 2006.
[53] J. Shrout, M. Yousefzadeh, A. Dodd et al., “β-2 microglobulin mRNA expression levels are prognostic for lymph node metastasis in colorectal cancer patients,” British Journal of Cancer, vol. 98, no. 12, pp. 1999–2005, 2008.